Logo image of ZEG.DE

ASTRAZENECA PLC (ZEG.DE) Stock Overview

Europe - FRA:ZEG - GB0009895292 - Common Stock

126.35 EUR
+0.75 (+0.6%)
Last: 9/26/2025, 7:00:00 PM

ZEG.DE Key Statistics, Chart & Performance

Key Statistics
52 Week High147.85
52 Week Low111
Market Cap391.75B
Shares3.10B
Float2.99B
Yearly Dividend2.56
Dividend Yield2.23%
EPS(TTM)7.57
PE16.69
Fwd PE13.91
Earnings (Next)11-06 2025-11-06/bmo
IPO09-21 2007-09-21
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


ZEG.DE short term performance overview.The bars show the price performance of ZEG.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 4 -4 -6

ZEG.DE long term performance overview.The bars show the price performance of ZEG.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 -5 10

The current stock price of ZEG.DE is 126.35 EUR. In the past month the price decreased by -7.3%. In the past year, price decreased by -9.65%.

ASTRAZENECA PLC / ZEG Daily stock chart

ZEG.DE Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1LLY.MI ELI LILLY & CO 44.49 582.83B
LLY.DE ELI LILLY & CO 44.47 582.55B
JNJ.DE JOHNSON & JOHNSON 17.87 368.86B
1JNJ.MI JOHNSON & JOHNSON 17.54 360.34B
RHO.DE ROCHE HOLDING AG-BR 13.49 230.15B
NOV.DE NOVO NORDISK A/S-B 14.11 209.37B
NOT.DE NOVARTIS AG-REG 14.06 203.88B
1SAN.MI SANOFI 10.63 195.68B
SAN.PA SANOFI 10.37 191.02B
SNW.DE SANOFI 10.36 190.85B
6MK.DE MERCK & CO. INC. 10.11 166.60B
PFE.DE PFIZER INC 6.99 115.19B

About ZEG.DE

Company Profile

ZEG logo image AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.

Company Info

ASTRAZENECA PLC

1 Francis Crick Avenue, Cambridge Biomedical Campus

CAMBRIDGE CAMBRIDGESHIRE GB

Employees: 94300

ZEG Company Website

ZEG Investor Relations

Phone: 442073045000

ASTRAZENECA PLC / ZEG.DE FAQ

What is the stock price of ASTRAZENECA PLC today?

The current stock price of ZEG.DE is 126.35 EUR. The price increased by 0.6% in the last trading session.


What is the ticker symbol for ASTRAZENECA PLC stock?

The exchange symbol of ASTRAZENECA PLC is ZEG and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is ZEG.DE stock listed?

ZEG.DE stock is listed on the Deutsche Boerse Ag exchange.


What is the price forecast or stock price prediction for ASTRAZENECA PLC stock?

34 analysts have analysed ZEG.DE and the average price target is 156.64 EUR. This implies a price increase of 23.97% is expected in the next year compared to the current price of 126.35. Check the ASTRAZENECA PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ASTRAZENECA PLC worth?

ASTRAZENECA PLC (ZEG.DE) has a market capitalization of 391.75B EUR. This makes ZEG.DE a Mega Cap stock.


How many employees does ASTRAZENECA PLC have?

ASTRAZENECA PLC (ZEG.DE) currently has 94300 employees.


What are the support and resistance levels for ASTRAZENECA PLC (ZEG.DE) stock?

ASTRAZENECA PLC (ZEG.DE) has a support level at 122.95 and a resistance level at 129.33. Check the full technical report for a detailed analysis of ZEG.DE support and resistance levels.


Is ASTRAZENECA PLC (ZEG.DE) expected to grow?

The Revenue of ASTRAZENECA PLC (ZEG.DE) is expected to grow by 9.68% in the next year. Check the estimates tab for more information on the ZEG.DE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ASTRAZENECA PLC (ZEG.DE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ASTRAZENECA PLC (ZEG.DE) stock pay dividends?

ASTRAZENECA PLC (ZEG.DE) has a dividend yield of 2.23%. The yearly dividend amount is currently 2.56. Check the full fundamental report for a detailed analysis of ZEG.DE dividend history, reliability and sustainability.


When does ASTRAZENECA PLC (ZEG.DE) report earnings?

ASTRAZENECA PLC (ZEG.DE) will report earnings on 2025-11-06, before the market open.


What is the Price/Earnings (PE) ratio of ASTRAZENECA PLC (ZEG.DE)?

The PE ratio for ASTRAZENECA PLC (ZEG.DE) is 16.69. This is based on the reported non-GAAP earnings per share of 7.57 and the current share price of 126.35 EUR. Check the full fundamental report for a full analysis of the valuation metrics for ZEG.DE.


ZEG.DE Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ZEG.DE. When comparing the yearly performance of all stocks, ZEG.DE is a bad performer in the overall market: 75.97% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ZEG.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE. While ZEG.DE belongs to the best of the industry regarding profitability, there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ZEG.DE Financial Highlights

Over the last trailing twelve months ZEG.DE reported a non-GAAP Earnings per Share(EPS) of 7.57. The EPS increased by 22.3% compared to the year before.


Industry RankSector Rank
PM (TTM) 14.68%
ROA 7.38%
ROE 18.55%
Debt/Equity 0.63
Chartmill High Growth Momentum
EPS Q2Q%9.6%
Sales Q2Q%11.74%
EPS 1Y (TTM)22.3%
Revenue 1Y (TTM)15%

ZEG.DE Forecast & Estimates

34 analysts have analysed ZEG.DE and the average price target is 156.64 EUR. This implies a price increase of 23.97% is expected in the next year compared to the current price of 126.35.

For the next year, analysts expect an EPS growth of 13.74% and a revenue growth 9.68% for ZEG.DE


Analysts
Analysts82.94
Price Target156.64 (23.97%)
EPS Next Y13.74%
Revenue Next Year9.68%

ZEG.DE Ownership

Ownership
Inst Owners48.98%
Ins Owners0.04%
Short Float %N/A
Short RatioN/A